GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lyell Immunopharma Inc (NAS:LYEL) » Definitions » Quick Ratio

Lyell Immunopharma (Lyell Immunopharma) Quick Ratio : 16.51 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Lyell Immunopharma Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Lyell Immunopharma's quick ratio for the quarter that ended in Mar. 2024 was 16.51.

Lyell Immunopharma has a quick ratio of 16.51. It generally indicates good short-term financial strength.

The historical rank and industry rank for Lyell Immunopharma's Quick Ratio or its related term are showing as below:

LYEL' s Quick Ratio Range Over the Past 10 Years
Min: 10.65   Med: 15.24   Max: 20.27
Current: 16.51

During the past 5 years, Lyell Immunopharma's highest Quick Ratio was 20.27. The lowest was 10.65. And the median was 15.24.

LYEL's Quick Ratio is ranked better than
89.37% of 1543 companies
in the Biotechnology industry
Industry Median: 3.6 vs LYEL: 16.51

Lyell Immunopharma Quick Ratio Historical Data

The historical data trend for Lyell Immunopharma's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lyell Immunopharma Quick Ratio Chart

Lyell Immunopharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
19.97 12.53 13.40 17.59 16.07

Lyell Immunopharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.27 17.63 16.74 16.07 16.51

Competitive Comparison of Lyell Immunopharma's Quick Ratio

For the Biotechnology subindustry, Lyell Immunopharma's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lyell Immunopharma's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lyell Immunopharma's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Lyell Immunopharma's Quick Ratio falls into.



Lyell Immunopharma Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Lyell Immunopharma's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(554.686-0)/34.519
=16.07

Lyell Immunopharma's Quick Ratio for the quarter that ended in Mar. 2024 is calculated as

Quick Ratio (Q: Mar. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(534.165-0)/32.353
=16.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lyell Immunopharma  (NAS:LYEL) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Lyell Immunopharma Quick Ratio Related Terms

Thank you for viewing the detailed overview of Lyell Immunopharma's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Lyell Immunopharma (Lyell Immunopharma) Business Description

Traded in Other Exchanges
N/A
Address
201 Haskins Way, South San Francisco, CA, USA, 94080
Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors. Its pipeline includes CARs (Chimeric antigen receptors), TILs (Tumor-infiltrating lymphocytes), and TCRs (T cell receptors).
Executives
Richard Klausner director, officer: Executive Chairman 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Matthew Lang officer: Chief Business Officer C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Rahsaan Thompson officer: Chief Legal Officer 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Tina M. Albertson officer: Chief Medical Officer C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO CA 94080
Gary K. Lee officer: Chief Scientific Officer C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO CA 94080
Cathy Friedman director C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005
Arch Venture Fund Ix Overage, L.p. 10 percent owner 8725 W. HIGGINS ROAD, SUITE 290, CHICAGO IL 60631
Elizabeth Homans director, officer: Chief Executive Officer C/O LYELL IMMUNOPHARMA, INC., 400 EAST JAMIE COURT, SUITE 301, SOUTH SAN FRANCISCO CA 94080
Stephen J. Hill officer: Chief Technical Ops. Officer C/O LYELL IMMUNOPHARMA, INC., 400 EAST JAMIE COURT, SUITE 301, SOUTH SAN FRANCISCO CA 94080
Charles W. Newton officer: Chief Financial Officer 46 FREDRICK AVENUE, ATHERTON CA 94027
Otis W Brawley director 5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518
Elizabeth G Nabel director BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115
William Jl Rieflin director NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Arch Venture Partners Ix, Llc 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Ix, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631